| Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
|---|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 | 0 |
| % | 0 | 0 | 0 | 0 | 0 |
The Captial Market (CapitalMarket.com) rating for Sai Life Sciences IPO is 48. Their analysis recommends May Subscribe for the IPO.
| Reviewer | Rating Score | Rating |
|---|---|---|
| Capital Market | 48 | May Subscribe |
[Dilip Davda] The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development serving over 25 world’s leading pharma companies. It marked steady growth in its top lines, but the sudden boost in bottom lines for FY24 raises eyebrows. Based on FY25 annualized earnings, the issue appears aggressively priced. Well-informed/cash surplus/risk seekers may park moderate funds for long term. Read detail review...
Sai Life Sciences Limited peer comparison with similar listed entities. (As on March 28, 2024)
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Sai Life Sciences Limited | 4.57 | 4.53 | 53.83 | 8.5 | Consolidated | ||
| DIVI'S LABORATORIES Limited | 60.27 | 60.27 | 511.21 | 103.04 | 11.79 | 6.72 | Consolidated |
| Suven Pharmaceuticals Limited | 11.8 | 11.8 | 94.04 | 109.37 | 14.64 | 7.2 | Consolidated |
| Syngene International Ltd | 12.71 | 12.69 | 105.91 | 73.59 | 11.98 | 6.69 | Consolidated |
Notes:
Sai Life Sciences IPO Reviews, analysis and views by popular members. Read Sai Life Sciences Ltd. IPO reviews by retail investors to find recommended ipo to buy.
| Review By | Apply | May Apply | Neutral | Avoid |
|---|---|---|---|---|
| Count | 0 | 0 | 0 | 0 |
| % | 0.00 | 0.00 | 0.00 | 0.00 |
| Member | Review |
|---|---|
| No recommendation found. Be the first to post the recommendation. | |
Note:
Free Equity Delivery
Flat ₹10 per Trade in Intraday & F&O
RHP
